Johnson & Johnson Offers $5.5 Billion to Resolve Decades of Ovarian Talc Claims

Strategic Resolution After Federal Court Shift

Johnson & Johnson has initiated a formal proposal to settle the vast majority of its domestic ovarian talc litigation. This move follows a significant ruling in federal Multi-District Litigation (MDL) that challenged the scientific basis of the plaintiffs' arguments. The court required claimants to provide specific proof of causation after expert witnesses in two primary bellwether cases retracted their testimony. This shift in the legal environment provided the momentum for the company to move toward a mass settlement.

Financial Terms and Participation Requirements

The proposed resolution involves a total financial commitment of US$5.5 billion. If the plan moves forward, the payment structure will be distributed over several years:

• Initial payments totaling up to $3 billion are slated for 2027.
• Secondary installments are scheduled to commence no earlier than 2028.

For the settlement to become final, it requires the consent of at least 95% of the remaining 76,000 claimants. This high threshold ensures that the agreement provides a definitive end to the litigation rather than leaving a substantial number of active cases in the system.

Defending Product Safety Standards

Despite the multibillion-dollar offer, Johnson & Johnson maintains its long-standing defense regarding the safety of its cosmetic talc. The company asserts that its products are free of asbestos and do not cause cancer. This proposal aims to conclude a 15-year legal battle that has significantly impacted the cosmetics and personal care industry. By moving toward a settlement, the company seeks to eliminate long-term legal volatility while emphasizing that mass tort litigation must rely on rigorous scientific evidence.

Source: Global Cosmetics News